India Pharma Outlook Team | Saturday, 26 July 2025
Pfizer has entered a worldwide license deal, with the exception of China, with Chinese company 3SBio to obtain exclusive rights to develop, make, and sell 3SBio's investigational bispecific antibody, SSGJ-707. The drug is an anti-PD-1 and anti-VEGF and was developed by applying 3SBio's proprietary CLF2 platform, a strategic move for Pfizer to expand on next-generation cancer medicines.
SSGJ-707 is similarly being explored in China in clinical trials in non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecologic cancers. Interim Phase 2 data at the American Society of Clinical Oncology (ASCO) Annual Meeting were promising in NSCLC patients for safety and efficacy. Commercial production of the drug substance will be initiated by Pfizer at its Sanford, North Carolina, site and the drug product at McPherson, Kansas. Phase 3 trials in the global sites, including the United States and international locations, will start in the near future.
Also Read: Mass Spectrometry in Biomarker Discovery for Early Disease Detection
“We are excited to be in a position to leverage our extensive experience and expertise to help develop SSGJ-707 in major tumor types,” said Chris Boshoff, Chief Scientific Officer and President of Pfizer's Research and Development. He emphasized the promise of SSGJ-707 to augment Pfizer's portfolio of antibody-drug conjugates.
As part of the deal, 3SBio will receive an initial payment of $1.25 billion and an equity investment of $100 million from Pfizer. A Pfizer option to acquire exclusive rights to SSGJ-707 in China is also included in the deal, which can earn an additional $150 million in option payments for 3SBio.
The alliance reaffirms Pfizer's leadership in the development of immuno-oncology and in bringing breakthrough treatments to cancer patients globally.
